| Year |
Citation |
Score |
| 2024 |
Gray JE, Markovets A, Reungwetwattana T, Majem M, Nogami N, Peled N, Lee JS, Cho BC, Chewaskulyong B, John T, Han JY, Sebastian M, Todd A, Rukazenkov Y, Barrett C, ... Chmielecki J, et al. Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During Treatment: Data From FLAURA and AURA3. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 39029876 DOI: 10.1016/j.jtho.2024.07.008 |
0.389 |
|
| 2024 |
Hobor S, Al Bakir M, Hiley CT, Skrzypski M, Frankell AM, Bakker B, Watkins TBK, Markovets A, Dry JR, Brown AP, van der Aart J, van den Bos H, Spierings D, Oukrif D, Novelli M, ... ... Chmielecki J, et al. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nature Communications. 15: 4871. PMID 38871738 DOI: 10.1038/s41467-024-47606-9 |
0.461 |
|
| 2023 |
Johnson M, Serra Traynor C, Vishwanathan K, Overend P, Hartmaier R, Markovets A, Chmielecki J, Mugundu GM, Barrett JC, Tomkinson H, Ramalingam SS. Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer. Clinical Pharmacology and Therapeutics. PMID 38010260 DOI: 10.1002/cpt.3113 |
0.315 |
|
| 2023 |
Gray JE, Han JY, Telaranta-Keerie A, Huang X, Kohlmann A, Hodge R, Rukazenkov Y, Chmielecki J, Espenschied CR, Lefterova M, Wu YL, Ramalingam SS, Barrett JC, Odegaard JI. Pan-tumor analytical validation and osimertinib clinical validation in EGFR mutant non-small cell lung cancer, supporting the first next generation sequencing liquid biopsy in vitro diagnostic. The Journal of Molecular Diagnostics : Jmd. PMID 37981090 DOI: 10.1016/j.jmoldx.2023.10.002 |
0.407 |
|
| 2023 |
Gray JE, Ahn MJ, Oxnard GR, Shepherd FA, Imamura F, Cheng Y, Okamoto I, Cho BC, Lin MC, Wu YL, Majem M, Gautschi O, Boyer M, Bulusu KC, Markovets A, ... ... Chmielecki J, et al. Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37379430 DOI: 10.1158/1078-0432.CCR-22-3146 |
0.325 |
|
| 2023 |
Chmielecki J, Gray JE, Cheng Y, Ohe Y, Imamura F, Cho BC, Lin MC, Majem M, Shah R, Rukazenkov Y, Todd A, Markovets A, Barrett JC, Hartmaier RJ, Ramalingam SS. Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications. 14: 3179. PMID 37263992 DOI: 10.1038/s41467-023-38999-0 |
0.356 |
|
| 2023 |
Chmielecki J, Mok T, Wu YL, Han JY, Ahn MJ, Ramalingam SS, John T, Okamoto I, Yang JC, Shepherd FA, Bulusu KC, Laus G, Collins B, Barrett JC, Hartmaier RJ, et al. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature Communications. 14: 1071. PMID 36849516 DOI: 10.1038/s41467-023-35962-x |
0.402 |
|
| 2023 |
Chmielecki J, Gray JE, Cheng Y, Ohe Y, Imamura F, Cho BC, Lin MC, Majem M, Shah R, Rukazenkov Y, Todd A, Markovets A, Barrett JC, Hartmaier RJ, Ramalingam SS. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications. 14: 1070. PMID 36849494 DOI: 10.1038/s41467-023-35961-y |
0.383 |
|
| 2021 |
Yu HA, Goldberg SB, Le X, Piotrowska Z, Goldman JW, De Langen AJ, Okamoto I, Cho BC, Smith P, Mensi I, Ambrose H, Kraljevic S, Maidment J, Chmielecki J, Li-Sucholeiki X, et al. Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). Clinical Lung Cancer. PMID 34389237 DOI: 10.1016/j.cllc.2021.06.006 |
0.386 |
|
| 2021 |
Vaclova T, Grazini U, Ward L, O'Neill D, Markovets A, Huang X, Chmielecki J, Hartmaier R, Thress KS, Smith PD, Barrett JC, Downward J, de Bruin EC. Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers. Nature Communications. 12: 1780. PMID 33741979 DOI: 10.1038/s41467-021-22057-8 |
0.376 |
|
| 2020 |
Smith HW, Yang L, Ling C, Walsh A, Martinez VD, Boucher J, Zuo D, Sokol ES, Pavlick DC, Frampton GM, Chmielecki J, Jones LM, Roux PP, Lockwood WW, Muller WJ. An ErbB2 splice variant lacking exon 16 drives lung carcinoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 32727899 DOI: 10.1073/Pnas.2007474117 |
0.46 |
|
| 2020 |
Gray JE, Han J, Telaranta-Keerie A, Huang X, Kohlmann A, Hodge R, Rukazenkov Y, Chmielecki J, Espenschied CR, Wu Y, Ramalingam SS, Barrett JC, Odegaard JI. Clinical performance of a comprehensive novel liquid biopsy test for identifying non-small cell lung cancer (NSCLC) patients for treatment with osimertinib. Journal of Clinical Oncology. 38: 9553-9553. DOI: 10.1200/Jco.2020.38.15_Suppl.9553 |
0.433 |
|
| 2020 |
Vishwanathan K, Dunyak J, Overend P, Hartmaier R, Markovets A, Chmielecki J, Mugundu G, Barrett C, Tomkinson H, Johnson M. Abstract CT024: Utility of longitudinal circulating tumor DNA (ctDNA) modeling to predict RECIST-defined progression in first-line patients with epidermal growth factor receptor mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC) Tumor Biology. DOI: 10.1158/1538-7445.Am2020-Ct024 |
0.451 |
|
| 2019 |
Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, et al. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900457. PMID 31809241 DOI: 10.1200/Jco.19.00457 |
0.474 |
|
| 2019 |
Brown H, Vansteenkiste J, Nakagawa K, Cobo M, John T, Barker C, Kohlmann A, Todd A, Saggese M, Chmielecki J, Markovets A, Scott M, Ramalingam SS. Brief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31605792 DOI: 10.1016/J.Jtho.2019.09.009 |
0.45 |
|
| 2019 |
Jonsson P, Lin AL, Young RJ, DiStefano NM, Hyman DM, Li BT, Berger MF, Zehir A, Ladanyi M, Solit DB, Arnold AG, Stadler ZK, Mandelker D, Goldberg ME, Chmielecki J, et al. Genomic correlates of disease progression and treatment response in prospectively characterized gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31263031 DOI: 10.1158/1078-0432.Ccr-19-0032 |
0.315 |
|
| 2019 |
Zhou C, Imamura F, Cheng Y, Okamoto I, Cho BC, Lin MC, Majem M, Gautschi O, Gray JE, Boyer MJ, Chmielecki J, Hartmaier R, Bulusu K, Barrett JC, Hodge R, et al. Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial. Journal of Clinical Oncology. 37: 9020-9020. DOI: 10.1200/Jco.2019.37.15_Suppl.9020 |
0.419 |
|
| 2019 |
Moore KN, Chambers SK, Hamilton EP, Chen L, Oza AM, Ghamande SA, Konecny GE, Plaxe SC, Spitz DL, Geenen JJJ, Troso-Sandoval TA, Cragun JM, Imedio ER, Kumar S, Mugundu GM, ... ... Chmielecki J, et al. Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study. Journal of Clinical Oncology. 37: 5513-5513. DOI: 10.1200/Jco.2019.37.15_Suppl.5513 |
0.322 |
|
| 2019 |
Hamilton E, Falchook GS, Wang JS, Fu S, Oza A, Karen S, Imedio ER, Kumar S, Ottesen L, Mugundu GM, Chmielecki J, Jones S, Spigel DR, Li BT. Abstract CT025: Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: Dose escalation Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct025 |
0.308 |
|
| 2019 |
Falchook GS, Sachdev J, Imedio ER, Kumar S, Mugundu G, Chmielecki J, Jones S, Spigel DR, Johnson M. Abstract CT022: A Phase Ib study of Wee1 inhibitor adavosertib in patients with advanced solid tumors Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct022 |
0.333 |
|
| 2019 |
Bauer TM, Moore K, Rader JS, Simpkins F, Mita A, Beck JT, Hart L, Chu Q, Oza A, Tinker AV, So K, Imedio ER, Kumar S, Mugundu GM, Jenkins S, ... Chmielecki J, et al. Abstract CT012: Open-label, multicenter, Phase Ib study to assess safety, tolerability and efficacy of adavosertib monotherapy in patients with advanced solid tumors: Expansion cohorts Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct012 |
0.394 |
|
| 2019 |
Reungwetwattana T, Gray J, Markovets A, Nogami N, Lee JS, Cho BC, Chewaskulyong B, Majem M, Peled N, Vishwanathan K, Todd A, Rukazenkov Y, Johnson M, Barrett C, Chmielecki J, et al. Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz446.016 |
0.32 |
|
| 2019 |
Yu H, Goldberg S, Le X, Piotrowska Z, Smith P, Mensi I, Kirova B, Chmielecki J, Li-Sucholeicki X, Szekeres P, Doughton G, Patel G, Jewsbury P, Riess J. P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.1366 |
0.309 |
|
| 2018 |
Papadimitrakopoulou VA, Wu YL, Han JY, Ahn MJ, Ramalingam SS, John T, Okamoto I, Yang JC, Bulusu KC, Laus G, Collins B, Barrett JC, Chmielecki J, Mok TSK. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii741. PMID 32138033 DOI: 10.1093/Annonc/Mdy424.064 |
0.391 |
|
| 2018 |
Hong MH, Kim MH, Kim SY, Heo SG, Kang HN, Park CW, Barrett JC, Stetson D, Chmielecki J, Markovets A, Kim HR, Cho BC. Molecular landscape of osimertinib resistance revealed by targeted panel sequencing and patient-derived cancer models in non-small cell lung cancer patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii516. PMID 32137338 DOI: 10.1093/Annonc/Mdy292.051 |
0.444 |
|
| 2018 |
Charo LM, Burgoyne AM, Fanta PT, Patel H, Chmielecki J, Sicklick JK, McHale MT. A NovelFusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 238-242. PMID 29523662 DOI: 10.6004/Jnccn.2017.7039 |
0.374 |
|
| 2018 |
Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, Morley S, Rosenzweig M, Gay LM, Goldberg ME, Suh J, Ali S, Ross J, Leyland-Jones B, Young B, ... ... Chmielecki J, et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy resistant breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29360925 DOI: 10.1093/Annonc/Mdy025 |
0.346 |
|
| 2018 |
Chmielecki J, Lai Z, Potts K, Garg K, Li M, Barrett JC. Abstract 5582: Use of circulating tumor DNA (ctDNA) to predict superiority of dosing schedules in early clinical development Cancer Research. 78: 5582-5582. DOI: 10.1158/1538-7445.Am2018-5582 |
0.411 |
|
| 2018 |
Oza A, Cibula D, Oaknin A, Poole C, Mathijssen R, Sonke G, Colombo N, Špaček J, Vuylsteke P, Hirte H, Pfisterer J, Plante M, Hanker L, Fielding A, Haddad V, ... Chmielecki J, et al. Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy Annals of Oncology. 29: viii340. DOI: 10.1093/Annonc/Mdy285.158 |
0.34 |
|
| 2018 |
Brown H, Vansteenkiste J, Nakagawa K, Cobo Dols M, John T, Barker C, Kohlmann A, Todd A, Saggese M, Chmielecki J, Markovets A, Ramalingam S. MA15.03 PD-L1 Expression in Untreated EGFRm Advanced NSCLC and Response to Osimertinib and SoC EGFR-TKIs in the FLAURA Trial Journal of Thoracic Oncology. 13: S408. DOI: 10.1016/J.Jtho.2018.08.441 |
0.315 |
|
| 2017 |
Albacker LA, Wu J, Smith P, Warmuth M, Stephens PJ, Zhu P, Yu L, Chmielecki J. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. Plos One. 12: e0176181. PMID 29121062 DOI: 10.1371/Journal.Pone.0176181 |
0.429 |
|
| 2017 |
Bieg-Bourne CC, Millis SZ, Piccioni DE, Fanta PT, Goldberg ME, Chmielecki J, Parker BA, Kurzrock R. Next-generation sequencing in the clinical setting clarifies patient characteristics and potential actionability. Cancer Research. PMID 28939679 DOI: 10.1158/0008-5472.Can-17-1569 |
0.445 |
|
| 2017 |
Wang L, Basturk O, Wang J, Benayed R, Middha S, Zehir A, Linkov I, Rao M, Aryeequaye R, Cao L, Chmielecki J, Ross J, Stephens PJ, Adsay V, Askan G, et al. A FISH assay efficiently screens for BRAF gene rearrangements in pancreatic acinar-type neoplasms. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 28884748 DOI: 10.1038/Modpathol.2017.106 |
0.409 |
|
| 2017 |
Parachoniak CA, Rankin A, Gaffney B, Hartmaier R, Spritz D, Erlich RL, Miller VA, Morosini D, Stephens P, Ross JS, Keech J, Chmielecki J. Exceptional Durable Response to Everolimus in a Patient with Biphenotypic Breast Cancer Harboring an STK11 Variant. Cold Spring Harbor Molecular Case Studies. PMID 28550065 DOI: 10.1101/mcs.a000778 |
0.332 |
|
| 2017 |
Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, Huang F, He Y, Sun J, Tabori U, Kennedy M, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Medicine. 9: 34. PMID 28420421 DOI: 10.1186/S13073-017-0424-2 |
0.357 |
|
| 2017 |
Hartmaier RJ, Albacker L, Chmielecki J, Bailey M, He J, Goldberg M, Ramkissoon S, Suh J, Elvin JA, Chiacchia S, Frampton GM, Ross JS, Miller V, Stephens PJ, Lipson D. High-throughput genomic profiling of adult solid tumors reveals novel insights into cancer pathogenesis. Cancer Research. PMID 28235761 DOI: 10.1158/0008-5472.Can-16-2479 |
0.523 |
|
| 2017 |
Hartmaier RJ, Charo J, Fabrizio D, Goldberg ME, Albacker LA, Pao W, Chmielecki J. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies. Genome Medicine. 9: 16. PMID 28231819 DOI: 10.1186/S13073-017-0408-2 |
0.58 |
|
| 2017 |
Chmielecki J, Bailey M, He J, Elvin J, Vergilio JA, Ramkissoon S, Suh J, Frampton GM, Sun JX, Morley S, Spritz D, Ali S, Gay L, Erlich RL, Ross JS, et al. Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. Cancer Research. PMID 28069802 DOI: 10.1158/0008-5472.Can-16-1106 |
0.512 |
|
| 2017 |
Thress KS, Markovets A, Barrett JC, Chmielecki J, Goldberg SB, Shepherd FA, Vowler S, Oxnard GR. Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial. Journal of Clinical Oncology. 35: 9018-9018. DOI: 10.1200/Jco.2017.35.15_Suppl.9018 |
0.388 |
|
| 2017 |
Priedigkeit N, Hartmaier R, Chen Y, Vareslija D, Basudan A, Thomas R, Leone J, Lucas P, Bhargava R, Hamilton R, Chmielecki J, Davidson N, Oesterreich S, Brufsky A, Young L, et al. Abstract PD1-05: Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquiredERBB2amplifications and activating mutations Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Pd1-05 |
0.325 |
|
| 2017 |
Spoerke J, Schleifman E, Clark T, Young G, Nahas M, Kennedy M, Young L, Chmielecki J, Otto G, Lipson D, Wilson T, Gendreau S, Lackner. Abstract P6-07-08: The complete spectrum ofESR1mutations from 7590 breast cancer tumor samples Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-07-08 |
0.451 |
|
| 2017 |
Hartmaier RJ, Priedigkeit N, Goldberg ME, Suh J, Ali S, Ross J, Tsai M, Haley B, Peguero J, Callahan RD, Sachelarie I, Cho J, Bahreini A, Puhalla SL, Oesterreich S, ... ... Chmielecki J, et al. Abstract 421: Comprehensive genomic analysis of metastatic breast cancers revealsESR1fusions as a recurrent mechanism of endocrine therapy resistance Cancer Research. 77: 421-421. DOI: 10.1158/1538-7445.Am2017-421 |
0.469 |
|
| 2017 |
Gupta A, Connelly C, Frampton G, Chmielecki J, Ali S, Suh J, Schrock A, Ross J, Stephens P, Miller V. P2.03b-068 The Druggable Mutation Landscape of Lung Adenocarcinoma Journal of Thoracic Oncology. 12: S977. DOI: 10.1016/J.Jtho.2016.11.1349 |
0.344 |
|
| 2016 |
Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, Corless CL, Hong D, Fero KE, Murphy JD, Fanta PT, Ali SM, De Siena M, Burgoyne AM, Movva S, et al. FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. Journal of Translational Medicine. 14: 339. PMID 27974047 DOI: 10.1186/S12967-016-1075-6 |
0.428 |
|
| 2016 |
Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Watters RJ, Thomas R, Leone JP, Lucas PC, Bhargava R, Hamilton RL, Chmielecki J, Puhalla SL, Davidson NE, Oesterreich S, et al. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases. Jama Oncology. PMID 27926948 DOI: 10.1001/Jamaoncol.2016.5630 |
0.378 |
|
| 2016 |
Meletath SK, Pavlick D, Brennan T, Hamilton R, Chmielecki J, Elvin JA, Palma N, Ross JS, Miller VA, Stephens PJ, Snipes G, Rajaram V, Ali SM, Melguizo-Gavilanes I. Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 1345-1350. PMID 27799506 DOI: 10.6004/Jnccn.2016.0145 |
0.378 |
|
| 2016 |
Tang CM, Lee TE, Syed SA, Burgoyne AM, Leonard SY, Gao F, Chan JC, Shi E, Chmielecki J, Morosini D, Wang K, Ross JS, Kendrick ML, Bardsley MR, De Siena M, et al. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression. Oncotarget. PMID 27793025 DOI: 10.18632/Oncotarget.12909 |
0.407 |
|
| 2016 |
Goldstein LD, Lee J, Gnad F, Klijn C, Schaub A, Reeder J, Daemen A, Bakalarski CE, Holcomb T, Shames DS, Hartmaier RJ, Chmielecki J, Seshagiri S, Gentleman R, Stokoe D. Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers. Cell Reports. PMID 27568559 DOI: 10.1016/J.Celrep.2016.08.010 |
0.401 |
|
| 2016 |
Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, et al. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies. Cancer. PMID 27284958 DOI: 10.1002/Cncr.30102 |
0.476 |
|
| 2016 |
Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, et al. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. The Oncologist. PMID 27245569 DOI: 10.1634/Theoncologist.2015-0497 |
0.444 |
|
| 2016 |
Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia C, Vergilio JA, Khan SA, Erlich RL, et al. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology. PMID 27207748 DOI: 10.1159/000445978 |
0.383 |
|
| 2016 |
Suh JH, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, Gay L, Elvin JA, Vergilio JA, Ali S, Miller VA, Stephens PJ, Ross JS. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. The Oncologist. PMID 27151654 DOI: 10.1634/Theoncologist.2016-0030 |
0.491 |
|
| 2016 |
Chung JH, Sanford E, Johnson A, Klempner SJ, Schrock AB, Palma NA, Erlich RL, Frampton GM, Chalmers ZR, Vergilio J, Rubinson DA, Sun JX, Chmielecki J, Yelensky R, Suh JH, et al. Comprehensive Genomic Profiling of Anal Squamous Cell Carcinoma Reveals Distinct Genomically Defined Classes. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 27052656 DOI: 10.1093/Annonc/Mdw152 |
0.412 |
|
| 2016 |
Foster SA, Whalen DM, Özen A, Wongchenko MJ, Yin J, Yen I, Schaefer G, Mayfield JD, Chmielecki J, Stephens PJ, Albacker LA, Yan Y, Song K, Hatzivassiliou G, Eigenbrot C, et al. Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2. Cancer Cell. PMID 26996308 DOI: 10.1016/J.Ccell.2016.02.010 |
0.433 |
|
| 2016 |
Schrock AB, Frampton GM, Herndon D, Greenbowe J, Wang K, Lipson D, Yelensky R, Chalmers Z, Chmielecki J, Elvin JA, Wollner M, Dvir A, Soussan-Guttman L, Bordonii R, Peled N, et al. Comprehensive Genomic Profiling Identifies Frequent Drug Sensitive EGFR Exon 19 Deletions in NSCLC Not Identified by Prior Molecular Testing. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26933124 DOI: 10.1158/1078-0432.Ccr-15-1668 |
0.426 |
|
| 2016 |
Rankin A, Schrock AB, Elvin JA, Chmielecki J, Erlich R, Morosini D, Frampton GM, Grothey A, Rosenblum A, Bufill JA, Helton DA, Sequeria J, George TJ, Klempner SJ, Ross JS, et al. Comprehensive genomic profiling of advanced colorectal carcinoma in the course of clinical care to identify KRAS insertions not detected by focused molecular testing. Journal of Clinical Oncology. 34: 497-497. DOI: 10.1200/Jco.2016.34.4_Suppl.497 |
0.507 |
|
| 2016 |
Elvin JA, Patterson C, Chalmers ZR, Ali SM, Brennan T, Chmielecki J, Stephens P, Boyle LE, Ross JS, Miller VA. Comprehensive genomic profiling (CGP) of advanced nonseminomatous testicular germ cell tumors (NSGCT) to reveal clinically relevant genomic alterations (CRGA) to guide targeted therapy. Journal of Clinical Oncology. 34: 477-477. DOI: 10.1200/Jco.2016.34.2_Suppl.477 |
0.469 |
|
| 2016 |
Chalmers ZR, Huang FW, Gay LM, Ali SM, Chmielecki J, Ross JS, Miller VA, Ganesan S, Stephens P, Garraway LA, Frampton GM. Analysis of tumor mutation burden (TMB) in >51,000 clinical cancer patients to identify novel non-coding PMS2 promoter mutations associated with increased TMB. Journal of Clinical Oncology. 34: 9572-9572. DOI: 10.1200/Jco.2016.34.15_Suppl.9572 |
0.506 |
|
| 2016 |
Albacker LA, Goldberg ME, Amler LC, Frampton GM, Ross JS, Suh J, Miller VA, Stephens P, Chmielecki J. DNA-based genomic profiling for classification of tissue of origin for patients with carcinoma of unknown primary site. Journal of Clinical Oncology. 34: 11519-11519. DOI: 10.1200/Jco.2016.34.15_Suppl.11519 |
0.319 |
|
| 2016 |
Ross J, Wang K, Johnson A, Watson J, Hatzis C, Pusztai L, Chmielecki J, Yelensky R, Lipson D, Elvin J, Vergilio J, Suh J, Miller V, Dicke K, Stephens P, et al. Abstract A32: MCL1 gene amplification in breast cancer is associated with TNBC status and can respond to a sorafenib/vorinostat regimen Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-A32 |
0.446 |
|
| 2016 |
Wang K, Ali S, Khaira D, Elvin J, Vergilio J, Suh J, Yelensky R, Lipson D, Chmielecki J, Miller V, Stephens P, Ross J. Abstract P6-03-12: Comprehensive genomic profiling of clinically advanced mucinous carcinoma of the breast Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-03-12 |
0.457 |
|
| 2016 |
Ali S, Wang K, Johnson A, Rodriguez A, Elvin J, Vergilio J, Suh J, Chumsri S, Morosini D, Yelensky R, Lipson D, Chmielecki J, Miller V, Ross J, Chang J, et al. Abstract P6-03-02: EGFR genomic alterations in 5,605 cases of refractory and metastatic breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-03-02 |
0.5 |
|
| 2016 |
Ross J, Wang K, Ali S, Chumsri S, Elvin J, Vergilio J, Suh J, Yelensky R, Lipson D, Chmielecki J, Miller V, Stephens P. Abstract P3-07-05: Non-amplification ERBB2 genomic alterations in 5,605 cases of refractory and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-07-05 |
0.494 |
|
| 2016 |
Massarweh S, Romond E, Stewart R, Sun J, Chmielecki J, Mehdi M, Black E. Abstract P3-05-06: Evolution of genomic alterations on endocrine therapy and mTOR inhibition in estrogen receptor (ER)-positive breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-05-06 |
0.501 |
|
| 2016 |
Pavlick D, Ali SM, Elvin JA, Stephens PJ, Miller VA, Ross JS, Suh JH, Vergilio J, Chmielecki J, Brennan T, Crawford JR, Malicki DM, Ahn H, Wong VN. Abstract A46: Identification of NTRK fusions in pediatric tumors via comprehensive genomic profiling Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-A46 |
0.469 |
|
| 2016 |
Chmielecki J, Bailey M, He J, Elvin J, Vergilio J, Ramkissoon S, Suh J, Frampton GM, Ali S, Ross J, Miller VA, Stephens PJ, Lipson D. Abstract LB-178: Genomic profiling of 1239 diverse pediatric cancers identifies novel discoveries across tumors Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-178 |
0.528 |
|
| 2016 |
Foster S, Whalen D, Ozen A, Wongchenko M, Yin J, Yen I, Schaefer G, Mayfield J, Chmielecki J, Stephens P, Albacker L, Yan Y, Song K, Hatzivassiliou G, Eigenbrot C, et al. Abstract 4374: Activation mechanism of oncogenic C-helix shifting mutations in BRAF, EGFR, and HER2 Cancer Research. 76: 4374-4374. DOI: 10.1158/1538-7445.Am2016-4374 |
0.47 |
|
| 2016 |
Chalmers ZR, Huang FW, Ali SM, Yelensky R, Chmielecki J, Ross JS, Miller VA, Stephens PJ, Garraway LA, Frampton GM. Abstract 3576: Broad analysis of recurrent somatic mutations in cancer reveals a common novel non-coding mutation in the promoter of PMS2 associated with greatly increased tumor mutation load Cancer Research. 76: 3576-3576. DOI: 10.1158/1538-7445.Am2016-3576 |
0.488 |
|
| 2016 |
Elvin JA, Chalmers ZR, Hou JY, Priore GD, Ali SM, Vergilio JA, Suh J, Chmielecki J, Frampton G, Lipson D, Stephens PJ, Miller V, Ross JS, Wright JD. Comprehensive genomic profiling of ovarian carcinomas identifies both ERBB2 amplifications and activating point mutations as biomarkers for anti-HER2 targeted therapy Gynecologic Oncology. 141: 176. DOI: 10.1016/J.Ygyno.2016.04.457 |
0.46 |
|
| 2016 |
Elvin J, Chalmers Z, Chudnovsky Y, Sun J, Hou J, Ali S, Vergilio J, Suh J, Chmielecki J, Frampton G, Del Priore G, Ross J, Castro M, Wright J, Gaillard S. Comprehensive genomic profiling of ovarian clear cell carcinomas identifies clinically relevant genomic alterations and targeted therapy options Gynecologic Oncology. 141: 175. DOI: 10.1016/J.Ygyno.2016.04.454 |
0.428 |
|
| 2015 |
Ali SM, Pal SK, Wang K, Palma NA, Sanford E, Bailey M, He J, Elvin JA, Chmielecki J, Squillace R, Dow E, Morosini D, Buell J, Yelensky R, Lipson D, et al. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations. The Oncologist. PMID 26670666 DOI: 10.1634/Theoncologist.2015-0241 |
0.407 |
|
| 2015 |
Williams CB, McMahon C, Ali SM, Abramovitz M, Williams KA, Klein J, McKean H, Yelensky R, George TJ, Elvin JA, Soman S, Lipson D, Chmielecki J, Morosini D, Miller VA, et al. A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. Oncotargets and Therapy. 8: 3561-3564. PMID 26664139 DOI: 10.2147/Ott.S90766 |
0.501 |
|
| 2015 |
Ross JS, Ali SM, Wang K, Khaira D, Palma NA, Chmielecki J, Palmer GA, Morosini D, Elvin JA, Fernandez SV, Miller VA, Stephens PJ, Cristofanilli M. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Breast Cancer Research and Treatment. PMID 26458824 DOI: 10.1007/S10549-015-3592-Z |
0.458 |
|
| 2015 |
Wang K, Johnson A, Ali SM, Klempner SJ, Bekaii-Saab T, Vacirca JL, Khaira D, Yelensky R, Chmielecki J, Elvin JA, Lipson D, Miller VA, Stephens PJ, Ross JS. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. The Oncologist. PMID 26336083 DOI: 10.1634/Theoncologist.2015-0156 |
0.315 |
|
| 2015 |
Ross JS, Wang K, Chmielecki J, Gay L, Johnson A, Chudnovsky J, Yelensky R, Lipson D, Ali SM, Elvin JA, Vergilio JA, Roels S, Miller VA, Nakamura BN, Gray A, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. International Journal of Cancer. Journal International Du Cancer. PMID 26314551 DOI: 10.1002/Ijc.29825 |
0.503 |
|
| 2015 |
Disel U, Germain A, Yilmazel B, Abali H, Bolat FA, Yelensky R, Elvin JA, Lipson D, Chmielecki J, Wang K, Stephens PJ, Ross JS, Miller VA, Ali SM, George TJ. Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification. Oncoscience. 2: 581-4. PMID 26244165 DOI: 10.18632/oncoscience.175 |
0.4 |
|
| 2015 |
Klempner SJ, Bazhenova LA, Braiteh FS, Nikolinakos PG, Gowen K, Cervantes CM, Chmielecki J, Greenbowe JR, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer (Amsterdam, Netherlands). 89: 357-9. PMID 26187428 DOI: 10.1016/J.Lungcan.2015.06.021 |
0.465 |
|
| 2015 |
Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, Palmer G, Yelensky R, Lipson DM, Chmielecki J, Erlich RL, Rankin AN, Ali SM, Elvin JA, Morosini D, et al. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. Jama Oncology. 1: 40-9. PMID 26182302 DOI: 10.1001/Jamaoncol.2014.216 |
0.338 |
|
| 2015 |
Crago AM, Chmielecki J, Rosenberg M, O'Connor R, Byrne C, Wilder FG, Thorn K, Agius P, Kuk D, Socci ND, Qin LX, Meyerson M, Hameed M, Singer S. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes, Chromosomes & Cancer. PMID 26171757 DOI: 10.1002/Gcc.22272 |
0.423 |
|
| 2015 |
Pal SK, Choueiri TK, Wang K, Khaira D, Karam JA, Van Allen E, Palma NA, Stein MN, Johnson A, Squillace R, Elvin JA, Chmielecki J, Yelensky R, Yakirevich E, Lipson D, et al. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. European Urology. PMID 26149668 DOI: 10.1016/J.Eururo.2015.06.019 |
0.306 |
|
| 2015 |
Subbiah V, McMahon C, Patel S, Zinner R, Silva EG, Elvin JA, Subbiah IM, Ohaji C, Ganeshan DM, Anand D, Levenback CF, Berry J, Brennan T, Chmielecki J, Chalmers ZR, et al. STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. Journal of Hematology & Oncology. 8: 66. PMID 26062823 DOI: 10.1186/S13045-015-0160-2 |
0.409 |
|
| 2015 |
Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SI, Salgia R, Brennan T, Chalmers ZR, et al. Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors. Cancer Discovery. PMID 25971938 DOI: 10.1158/2159-8290.Cd-15-0285 |
0.529 |
|
| 2015 |
Ali SM, Sanford EM, Klempner SJ, Rubinson DA, Wang K, Palma NA, Chmielecki J, Yelensky R, Palmer GA, Morosini D, Lipson D, Catenacci DV, Braiteh F, Erlich R, Stephens PJ, et al. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. The Oncologist. 20: 499-507. PMID 25882375 DOI: 10.1634/Theoncologist.2014-0378 |
0.443 |
|
| 2015 |
Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, Seepo S, Meyerson M, Pass HI. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Research. 75: 264-9. PMID 25488749 DOI: 10.1158/0008-5472.Can-14-1008 |
0.408 |
|
| 2015 |
Chmielecki J, Ross JS, Wang K, Frampton GM, Palmer GA, Ali SM, Palma N, Morosini D, Miller VA, Yelensky R, Lipson D, Stephens PJ. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. The Oncologist. 20: 7-12. PMID 25480824 DOI: 10.1634/Theoncologist.2014-0234 |
0.436 |
|
| 2015 |
Pal SK, Ali SM, Chalmers Z, Karam JA, Elvin JA, Chmielecki J, Yelensky R, Allen EMV, Lipson D, Wang K, Fay AP, Choueiri TK, Miller VA, Stephens P, Ross JS. Comprehensive genomic profiling of 443 cases of renal cell carcinoma to reveal frequent clinically relevant genomic alterations. Journal of Clinical Oncology. 33: 433-433. DOI: 10.1200/Jco.2015.33.7_Suppl.433 |
0.464 |
|
| 2015 |
Wang K, Chmielecki J, Ali SM, Elvin JA, Yelensky R, Lipson D, Miller VA, Stephens PJ, Ross JS. Comprehensive genomic profiling (CGP) of advanced stage esophageal squamous cell carcinomas (ESCC) and esophageal adenocarcinomas (EAC) to reveal similarities and differences. Journal of Clinical Oncology. 33: 7-7. DOI: 10.1200/Jco.2015.33.3_Suppl.7 |
0.48 |
|
| 2015 |
Ross JS, Wang K, Catenacci DVT, Chmielecki J, Ali SM, Elvin JA, Yelensky R, Lipson D, Hawryluk MJ, Miller VA, Stephens PJ, Javle MM. Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations. Journal of Clinical Oncology. 33: 231-231. DOI: 10.1200/Jco.2015.33.3_Suppl.231 |
0.546 |
|
| 2015 |
Pal SK, Ali SM, Chalmers Z, Karam JA, Elvin JA, Chmielecki J, Yelensky R, Allen EMV, Lipson D, Wang K, Fay AP, Miller VA, Stephens P, Ross JS, Choueiri TK. Comprehensive genomic profiling of 443 patients with advanced renal cell carcinoma (RCC) to reveal clinically relevant genomic alterations and to aid in classification of rare subtypes. Journal of Clinical Oncology. 33: 4520-4520. DOI: 10.1200/Jco.2015.33.15_Suppl.E19048 |
0.48 |
|
| 2015 |
Safra T, Rosengarten O, Korach J, Koren C, Siegelmann-Danieli N, Baruch NB, Merose R, Shpigel S, Beiner M, Greenberg J, Chmielecki J, Chalmers Z, Elvin JA, Stephens P, Dvir A, et al. Comprehensive genomic profiling (CGP) of gynecologic malignancies in Israeli population to reveal potentially clinically relevant genomic alterations and opportunities for targeted therapies. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E16578 |
0.408 |
|
| 2015 |
Blumenthal DT, Bokstein F, Limon D, Zach L, Lossos A, Tzuk T, Lokiec A, Ram Z, Dvir A, Soussan-Gutman L, Chalmers Z, Miller VA, Chmielecki J, Ali SM. Comprehensive genomic profiling of primary intracranial malignant neoplasms to reveal frequency of clinically relevant genomic alterations. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E13007 |
0.494 |
|
| 2015 |
Hawryluk MJ, Wang K, Khaira D, Chmielecki J, Ali SM, Elvin JA, Vergilio J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Ross JS. Comprehensive genomic profiling of salivary gland adenocarcinomas to reveal frequency of druggable targets. Journal of Clinical Oncology. 33: 6040-6040. DOI: 10.1200/Jco.2015.33.15_Suppl.6040 |
0.487 |
|
| 2015 |
Elvin JA, Bailey M, Carneiro BA, Ali SM, Vergilio J, Palma NA, Chmielecki J, Frampton GM, Lipson D, Stephens P, Miller VA, Johnson ML, Giles FJ, Ross JS, Dorigo O. Comprehensive genomic profiling (CGP) of cervical squamous cell carcinoma (cSCC) to identifiy targeted therapy options. Journal of Clinical Oncology. 33: 5602-5602. DOI: 10.1200/Jco.2015.33.15_Suppl.5602 |
0.408 |
|
| 2015 |
Massarweh SA, Chmielecki J, Sun J, Stewart RL, Dressler EVM, Kadamyan V, Chambers MD, Horbinski C, Mehdi M, Black EP, Romond EH. Effect of mutations in distinct components of the PI3K/AKT/mTOR pathway on sensitivity to endocrine therapy in estrogen receptor (ER)-positive breast cancer. Journal of Clinical Oncology. 33: 532-532. DOI: 10.1200/Jco.2015.33.15_Suppl.532 |
0.446 |
|
| 2015 |
Black EP, Romond EH, Chmielecki J, Sun J, Kadamyan V, Chambers MD, Stewart RL, Dressler EVM, Mehdi M, Horbinski C, Massarweh SA. Evaluation of possible linkage between everolimus benefit in estrogen receptor (ER)-positive breast cancer and genomic alterations of the PI3K/AKT/mTOR pathway. Journal of Clinical Oncology. 33: 530-530. DOI: 10.1200/Jco.2015.33.15_Suppl.530 |
0.368 |
|
| 2015 |
Hawryluk MJ, Wang K, Ali SM, Fisher H, Mian B, Nazeer T, Elvin JA, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Ross JS. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder to reveal frequency of clinically relevant genomic alterations. Journal of Clinical Oncology. 33: 4526-4526. DOI: 10.1200/Jco.2015.33.15_Suppl.4526 |
0.44 |
|
| 2015 |
Ross JS, Wang K, Javle MM, Catenacci DVT, Shroff RT, Ali SM, Elvin JA, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Meric-Bernstam F. Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations. Journal of Clinical Oncology. 33: 4009-4009. DOI: 10.1200/Jco.2015.33.15_Suppl.4009 |
0.479 |
|
| 2015 |
Ross JS, Wang K, Khaira D, Johnson A, Chmielecki J, Ali SM, Elvin JA, Vergilio J, Yelensky R, Lipson D, Miller VA, Stephens PJ. Comprehensive genomic profiling of clinically advanced colorectal carcinoma to reveal frequent opportunities for targeted therapies. Journal of Clinical Oncology. 33: 3553-3553. DOI: 10.1200/Jco.2015.33.15_Suppl.3553 |
0.448 |
|
| 2015 |
Sanford EM, Ali SM, Elvin JA, Frampton GM, Sun J, Palma NA, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Ross JS. Comprehensive genomic profiling of anal squamous cell carcinoma to reveal frequency of clinically relevant genomic alterations in the PI3K/mTOR pathway. Journal of Clinical Oncology. 33: 3522-3522. DOI: 10.1200/Jco.2015.33.15_Suppl.3522 |
0.479 |
|
| 2015 |
Faiq N, Chmielecki J, Goldberg M, Stephens P, Kurzrock R, Kesari S, Piccioni DE. Analysis of BRAF alterations and molecular profiling in glioblastoma and astrocytoma. Journal of Clinical Oncology. 33: 2074-2074. DOI: 10.1200/Jco.2015.33.15_Suppl.2074 |
0.433 |
|
| 2015 |
Johnson A, Ali SM, Yelensky R, Chmielecki J, Elvin JA, Lipson D, Miller VA, Stephens PJ, Ross JS, Wang K. Comprehensive genomic profiling of advanced stage esophageal squamous cell carcinomas (ESCC) and esophageal adenocarcinomas (EAC). Journal of Clinical Oncology. 33: 1535-1535. DOI: 10.1200/Jco.2015.33.15_Suppl.1535 |
0.443 |
|
| 2015 |
Wang K, Johnson A, Garrido-Laguna I, Chmielecki J, Yelensky R, Lipson D, Elvin JA, Vergilio J, Ali SM, Miller VA, Stephens PJ, Ross JS. Amplification of CRKL in human cancer: A rare event associated with potential sensitivity to targeted therapy. Journal of Clinical Oncology. 33: 1526-1526. DOI: 10.1200/Jco.2015.33.15_Suppl.1526 |
0.53 |
|
| 2015 |
Morosini D, Chmielecki J, Goldberg M, Ross JS, Stephens PJ, Miller VA, Davis LE. Comprehensive genomic profiling of sarcomas from 267 adolescents and young adults to reveal a spectrum of targetable genomic alterations. Journal of Clinical Oncology. 33: 11020-11020. DOI: 10.1200/Jco.2015.33.15_Suppl.11020 |
0.356 |
|
| 2015 |
Wang K, Morosini D, Yelensky R, Lipson D, Chmielecki J, Ali SM, Ross JS, Stephens P, Miller VA. Abstract B06: Distinct genomic profiles and targetable alterations revealed by FoundationOne® Heme in hematolymphoid malignancies in adolescents and young adults. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-B06 |
0.472 |
|
| 2015 |
Palma NA, Ali S, Frampton G, Wang K, Gilmore H, Peguero J, Harris LN, Cristofanilli M, Chmielecki J, Ross JS, Morosini D, Miller VA, Stephens PJ, Palmer G, O'Shaughnessy J. Abstract PD6-5: Profiling of ESR1-mutated metastatic breast cancers by FoundationOne® allows a broad genomic understanding for potential clinical implications Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd6-5 |
0.474 |
|
| 2015 |
Palmer GA, Ross JS, Wang K, Frampton GM, Ali SM, Palma N, Morosini D, Miller VA, Yelensky R, Lipson D, Stephens PJ, Chmielecki J. Abstract P4-15-03: Activating mutations in ERBB2/HER2 as found by FoundationOneTM represent potential therapeutic targets in breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-15-03 |
0.483 |
|
| 2015 |
Palma NA, Chmielecki J, Frampton G, Ali S, Levin M, Ross JS, Morosini D, Palmer G, Miller VA, Stephens P, O'Shaughnessy J. Abstract P2-03-06: FoundationOne profiling of TSC1 and TSC2-mutated advanced breast cancers Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P2-03-06 |
0.468 |
|
| 2015 |
Chmielecki J, Goldberg ME, Fichtenholtz A, Elvin J, Frampton GM, Ali SM, Ross JS, Morosini D, Miller VA, Piccioni D, Kesari S, Stephens PJ. Abstract 4667: The complex genomic landscape of glial tumors reveals distinct subclasses and potential therapeutic targets associated with clinical responses to targeted inhibitors Cancer Research. 75: 4667-4667. DOI: 10.1158/1538-7445.Am2015-4667 |
0.414 |
|
| 2015 |
Frampton GM, Ali S, Chmielecki J, Rosenzweig M, Brennan T, Chalmers Z, Elvin J, Fichtenholtz A, Gowan K, Greenbowe J, Johnson A, Khaira L, Lipson D, McMahon C, Roels S, et al. Abstract 1118: Activation of MET via diverse exon 14 skipping mutations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors Cancer Research. 75: 1118-1118. DOI: 10.1158/1538-7445.Am2015-1118 |
0.422 |
|
| 2015 |
Rowland M, McMeekin S, Moore K, Bailey M, Ali SM, Zuna R, Vergilio J, Suh J, Chmielecki J, Frampton GM, Lipson D, Stephens PJ, Miller VA, Ross JS, Elvin JA. Abstract A79: Comprehensive genomic profiling (CGP) of adult granulosa cell tumors (aGCT) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A79 |
0.533 |
|
| 2015 |
Chalmers ZR, Ali SM, Frampton GM, Chmielecki J, Palma NA, Elvin JA, Johnson A, Yelensky R, Ross JS, Stephens PJ, Miller VA, Waanders AJ, Crawford J. GE-04 * COMPREHENSIVE GENOMIC PROFILING (CGP) OF PEDIATRIC GLIOMAS REVEALS A HIGH FREQUENCY OF CLINICALLY RELEVANT GENOMIC ALTERATIONS (CRGA) ASSOCIATED WITH BENEFIT FROM TARGETED THERAPY Neuro-Oncology. 17: iii7-iii8. DOI: 10.1093/Neuonc/Nov061.28 |
0.477 |
|
| 2015 |
Ali S, Wang K, Johnson A, Suh J, Heilmann A, Lipson D, Yelensky R, Chmielecki J, Elvin J, Konduri K, Subbiah V, Stephens P, Ross J, Miller V. 3007 Comprehensive genomic profiling characterizes the cpectrum of non-V600E activating BRAF alterations Including BRAF fusions in lung cancer European Journal of Cancer. 51: S597. DOI: 10.1016/S0959-8049(16)31652-5 |
0.462 |
|
| 2015 |
Wang K, Ganesan S, Johnson A, Sharman JP, Chachoua A, Hirshfield K, Aisner J, Yelensky R, Lipson D, Elvin JA, Chmielecki J, Stephens PJ, Ross JS, Miller VA, Ou SHI, et al. 2879 High prevalent BRAF alterations and tert promoter mutations in papillary thyroid carcinoma European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31616-1 |
0.312 |
|
| 2015 |
Heilmann A, Subbiah V, Wang K, Elvin J, Chmielecki J, Yelensky R, Vergilio JA, Erlich R, Lipson D, Ross J, Miller V, Ali S, Stephens P. 2813 Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31556-8 |
0.347 |
|
| 2015 |
Ali S, Choueiri T, Wang K, Khaira D, Johnson A, Squillace R, Elvin J, Chmielecki J, Yelensky R, Lipson D, Miller V, Ross J, Stein M, Pal S, Stephens P. 2651 Comprehensive genomic profiling (CGP) identifies unique and abundant clinically relevant genomic alterations in rare histologies of renal cell carcinoma European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31468-X |
0.374 |
|
| 2015 |
Ali S, Sanford E, Elvin J, Bailer M, He J, Wang K, Chmielecki J, Yelensky R, Morosini D, Lipson D, Frampton G, Chalmers Z, Stephens P, Ross J, Miller V, et al. 2641 Comprehensive genomic profiling of advanced penile carcinoma suggests a high rate of clinically relevant genomic alterations European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31458-7 |
0.381 |
|
| 2015 |
Ross J, Chalmers Z, Wang K, Yelensky R, Lipson D, Elvin J, Vergilio JA, Chmielecki J, Ali S, Miller V, Stephens P. 801 Therapeutically relevant extracellular domain mutations in ERBB2/HER2 are observed across multiple tumor types and are sssociated with major responses to anti-HER2 targeted therapies European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)30391-4 |
0.42 |
|
| 2015 |
Frampton G, Ali S, Rosenzweig M, Chmielecki J, Bauer T, Akimov M, Peters M, Bufill J, Lee C, Ou I, Salgia R, Yelensky R, Morosini D, Ross J, Philip S, et al. 464 Comprehensive genomic profiling of advanced cancers identifies MET exon 14 alterations that are sensitive to MET inhibitors European Journal of Cancer. 51: S99-S100. DOI: 10.1016/S0959-8049(16)30298-2 |
0.466 |
|
| 2015 |
Elvin J, Wang K, Ali S, Chmielecki J, Stephens P, Dorigo O, Ross J. Comprehensive genomic profiling of advanced stage endometrioid endometrial adenocarcinomas (EEAC) reveals differences associated with CTNNB1 mutation status and a high frequency of clinically relevant genomic alterations Gynecologic Oncology. 137: 65-66. DOI: 10.1016/J.Ygyno.2015.01.154 |
0.426 |
|
| 2014 |
Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, Chen J, Robinson HE, Shim HS, Chmielecki J, Pao W, Engelman JA, Iafrate AJ, Le LP. Anchored multiplex PCR for targeted next-generation sequencing. Nature Medicine. 20: 1479-84. PMID 25384085 DOI: 10.1038/Nm.3729 |
0.519 |
|
| 2014 |
Chmielecki J, Hutchinson KE, Frampton GM, Chalmers ZR, Johnson A, Shi C, Elvin J, Ali SM, Ross JS, Basturk O, Balasubramanian S, Lipson D, Yelensky R, Pao W, Miller VA, et al. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discovery. 4: 1398-405. PMID 25266736 DOI: 10.1158/2159-8290.Cd-14-0617 |
0.628 |
|
| 2014 |
Ross JS, Wang K, Rand JV, Gay L, Presta MJ, Sheehan CE, Ali SM, Elvin JA, Labrecque E, Hiemstra C, Buell J, Otto GA, Yelensky R, Lipson D, Morosini D, ... Chmielecki J, et al. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies. Journal of Clinical Pathology. 67: 968-73. PMID 25078331 DOI: 10.1136/Jclinpath-2014-202514 |
0.378 |
|
| 2014 |
Sharman JP, Chmielecki J, Morosini D, Palmer GA, Ross JS, Stephens PJ, Stafl J, Miller VA, Ali SM. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. Clinical Lymphoma, Myeloma & Leukemia. 14: e161-3. PMID 24997557 DOI: 10.1016/J.Clml.2014.06.004 |
0.439 |
|
| 2014 |
Ross JS, Wang K, Elkadi OR, Tarasen A, Foulke L, Sheehan CE, Otto GA, Palmer G, Yelensky R, Lipson D, Chmielecki J, Ali SM, Elvin J, Morosini D, Miller VA, et al. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. Journal of Clinical Pathology. 67: 772-6. PMID 24978188 DOI: 10.1136/Jclinpath-2014-202447 |
0.473 |
|
| 2014 |
Brooks AN, Choi PS, de Waal L, Sharifnia T, Imielinski M, Saksena G, Pedamallu CS, Sivachenko A, Rosenberg M, Chmielecki J, Lawrence MS, DeLuca DS, Getz G, Meyerson M. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. Plos One. 9: e87361. PMID 24498085 DOI: 10.1371/Journal.Pone.0087361 |
0.465 |
|
| 2014 |
Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discovery. 4: 216-31. PMID 24436047 DOI: 10.1158/2159-8290.Cd-13-0639 |
0.504 |
|
| 2014 |
Chmielecki J, Meyerson M. DNA sequencing of cancer: what have we learned? Annual Review of Medicine. 65: 63-79. PMID 24274178 DOI: 10.1146/Annurev-Med-060712-200152 |
0.412 |
|
| 2014 |
Hirshfield KM, Devries C, Chojecki AL, Ali SM, Yelensky R, Chmielecki J, Ross JS, Stephens PJ, Miller VA, Rodriguez L, Ganesan S. Therapeutic insights for malignant phyllodes from next-generation sequencing. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E22069 |
0.335 |
|
| 2014 |
Ali SM, Ou SI, He J, Peled N, Chmielecki J, Pinder MC, Palma NA, Akerley WL, Wang K, Molina JR, Ross JS, Yelensky R, Frampton GM, Bazhenova L, Palmer GA, et al. Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma. Journal of Clinical Oncology. 32: 8049-8049. DOI: 10.1200/Jco.2014.32.15_Suppl.8049 |
0.433 |
|
| 2014 |
Stephens P, Wang K, Palma NA, Chmielecki J, Shroff RT, Churi C, Frampton GM, Ali SM, Javle MM, Ross JS. Comprehensive genomic profiling of gallbladder adenocarcinoma and frequent genomic-derived targets of therapy. Journal of Clinical Oncology. 32: 4142-4142. DOI: 10.1200/Jco.2014.32.15_Suppl.4142 |
0.412 |
|
| 2014 |
Ross JS, Wang K, Otto G, Palmer GA, Yelensky R, Lipson D, Chmielecki J, Ali SM, Morosini D, Miller VA, Stephens P. Targeted next-generation sequencing (NGS) of carcinoma of unknown primary site (CUP): Actionable genomic alterations (GA) and new routes to targeted therapies. Journal of Clinical Oncology. 32: 11048-11048. DOI: 10.1200/Jco.2014.32.15_Suppl.11048 |
0.439 |
|
| 2014 |
Miller VA, Chmielecki J, Hutchinson K, Frampton GM, Ali SM, Ross JS, Shi C, Pao W, Klimstra DS, Yelensky R, Lipson D, Stephens P. Next-generation sequencing (NGS)-based profiling of pancreatic acinar cell carcinoma for identification of a recurrent SND1-BRAF fusion. Journal of Clinical Oncology. 32: 11029-11029. DOI: 10.1200/Jco.2014.32.15_Suppl.11029 |
0.625 |
|
| 2014 |
Morosini D, Wang K, Wagner KW, Yelensky R, Lipson D, Chmielecki J, Ali SM, Ross JS, Stephens P, Miller VA. Comprehensive genomic profiling of solid tumors from 677 adolescents and young adults for revealing a distinct spectrum of targetable genomic alterations. Journal of Clinical Oncology. 32: 11008-11008. DOI: 10.1200/Jco.2014.32.15_Suppl.11008 |
0.48 |
|
| 2014 |
Hawryluk MJ, Wang K, Chmielecki J, Ali SM, Palmer GA, Downing S, Curran J, Garcia L, White E, Lipson D, Yelensky R, Stephens PJ, Miller VA, Ross JS. Clinical application of comprehensive next-generation sequencing-based genomic profiling for identification of actionable genomic alterations in pediatric solid tumors and hematolymphoid malignancies: The Foundation Medicine pediatric experience. Journal of Clinical Oncology. 32: 10035-10035. DOI: 10.1200/Jco.2014.32.15_Suppl.10035 |
0.442 |
|
| 2014 |
Wang K, Morosini D, Yelensky R, Palma N, Johnson A, Lipson D, Chmielecki J, Ali S, Ross JS, Stephens PJ, Miller V. Genomic Alterations of Histone Modification Genes Are Significantly Less Common in Non-Hodgkin Lymphomas of Adolescents and Young Adults Compared to Older Patients Blood. 124: 1684-1684. DOI: 10.1182/Blood.V124.21.1684.1684 |
0.415 |
|
| 2014 |
Ali SM, Hawryluk MJ, Wang K, Chmielecki J, Palmer GA, Garcia L, White E, Yelensky R, Stephens PJ, Ross JS, Maris JM, Miller VA. Abstract A28: Clinical next-generation sequencing (NGS) reveals genomic alterations (GAs) to guide targeted therapy in advanced neuroblastoma patients Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-A28 |
0.451 |
|
| 2014 |
Hawryluk MJ, Wang K, Chmielecki J, Ali SM, Palmer G, Garcia L, White E, Yelensky R, Stephens PJ, Ross JS, Miller VA. Abstract A23: Comprehensive next-generation sequencing-based genomic profiling identifies actionable genomic alterations in diverse pediatric tumor types: The Foundation Medicine (FMI) experience Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-A23 |
0.522 |
|
| 2014 |
Shern JF, Chen L, Chmielecki J, Wei J, Patidar R, Song Y, Liao H, Brohl A, Catchpoole D, Badgett T, Getz G, Graupera J, Anderson J, Skapek SX, Barr FG, et al. Abstract A21: Integrative genome and transcriptome sequencing defines the landscape of genetic alterations underlying pediatric rhabdomyosarcoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-A21 |
0.511 |
|
| 2014 |
Yelensky R, Donahue A, Otto G, Nahas M, He J, Juhn F, Downing S, Frampton GM, Chmielecki J, Ross JS, Zakowski M, Ladanyi M, Miller VA, Stephens PJ, Lipson D. Abstract 4699: Analytical validation of solid tumor fusion gene detection in a comprehensive NGS-based clinical cancer genomic test Cancer Research. 74: 4699-4699. DOI: 10.1158/1538-7445.Am2014-4699 |
0.465 |
|
| 2014 |
Chmielecki J, Frampton G, Lipson D, He J, Otto G, Ali S, Ross JS, Miller VA, Yelensky R, Stephens PJ. Abstract 4268: An unbiased survey of cancer-related rearrangements in 5,917 solid tumors identifies therapeutically actionable fusions across multiple disease subtypes Cancer Research. 74: 4268-4268. DOI: 10.1158/1538-7445.Am2014-4268 |
0.506 |
|
| 2014 |
Chmielecki J, Frampton G, Morosini D, Ali S, Lipson D, Yelensky R, Ross J, Miller V, Stephens P. Ge-07The Genomic Landscape Of Diverse Brain Tumors Reveals Known And Novel Oncogenic Alterations Frequently Associated With Sensitivity To Targeted Inhibitors. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou256.7 |
0.537 |
|
| 2014 |
Morosini D, Wang K, Wagner K, Gershenhorn B, Yelensky R, Lipson D, Chmielecki J, Ali SM, Ross JS, Stephens PJ, Miller VA. 415 Comprehensive next generation sequencing of solid tumors from 669 adolescents and young adults reveals a distinct spectrum of targetable genomic alterations European Journal of Cancer. 50: 132-133. DOI: 10.1016/S0959-8049(14)70541-6 |
0.369 |
|
| 2014 |
Ali S, Sanford E, Hawryluk M, Chmielecki J, Wang K, Palmer G, Palma N, Morosini D, Erlich R, Yelensky R, Lipson D, Ross J, Mosse Y, Stephens P, Maris J, et al. 414 Genomic profiling using a clinical next generation sequencing (NGS) assay reveals genomic alterations to guide targeted therapy in advanced neuroblastoma patients European Journal of Cancer. 50: 132. DOI: 10.1016/S0959-8049(14)70540-4 |
0.425 |
|
| 2013 |
Chmielecki J, Crago AM, Rosenberg M, O'Connor R, Walker SR, Ambrogio L, Auclair D, McKenna A, Heinrich MC, Frank DA, Meyerson M. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nature Genetics. 45: 131-2. PMID 23313954 DOI: 10.1038/Ng.2522 |
0.362 |
|
| 2013 |
Brooks AN, Wan Y, Choi P, Jing R, DeLuca DS, Sougnez C, Chmielecki J, Imielinski M, Getz G, Wu CJ, Meyerson M. Abstract 3150: Characterizing the effects of somatic mutations in splice factors on the transcriptome. Cancer Research. 73: 3150-3150. DOI: 10.1158/1538-7445.Am2013-3150 |
0.328 |
|
| 2013 |
Chmielecki J, Rosenberg M, Imielinski M, Hernandez B, Lawrence M, Sivachenko A, Cibulskis K, Voet D, Sougnez C, Gabriel S, Getz G, Meyerson M. Abstract 1112: Whole exome and whole genome sequence analysis of lung adenocarcinoma. Cancer Research. 73: 1112-1112. DOI: 10.1158/1538-7445.Am2013-1112 |
0.523 |
|
| 2012 |
Foo J, Chmielecki J, Pao W, Michor F. Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 1583-93. PMID 22982659 DOI: 10.1097/Jto.0B013E31826146Ee |
0.612 |
|
| 2012 |
Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences of the United States of America. 109: E2127-33. PMID 22773810 DOI: 10.1073/Pnas.1203530109 |
0.649 |
|
| 2012 |
Chmielecki J, Pietanza MC, Aftab D, Shen R, Zhao Z, Chen X, Hutchinson K, Viale A, Kris MG, Stout T, Miller V, Rizvi N, Pao W. EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 434-42. PMID 22173702 DOI: 10.1097/Jto.0B013E31823C5Aee |
0.602 |
|
| 2012 |
Chmielecki J, Peifer M, Viale A, Hutchinson K, Giltnane J, Socci ND, Hollis CJ, Dean RS, Yenamandra A, Jagasia M, Kim AS, Davé UP, Thomas RK, Pao W. Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. Genes, Chromosomes & Cancer. 51: 54-65. PMID 21938754 DOI: 10.1002/Gcc.20930 |
0.576 |
|
| 2012 |
Ohashi K, Chmielecki J, Lin Y, Pan H, Vnencak-Jones C, Arcila M, Wang L, Fernandez L, Keisuke A, Shien K, Yamamoto H, Toyooka S, Kiura K, Thomas R, Yang JC, et al. Abstract 1897: RAS signaling pathway gene mutations and acquired resistance to EGFR tyrosine-kinase inhibitors in EGFR mutant lung cancer Cancer Research. 72: 1897-1897. DOI: 10.1158/1538-7445.Am2012-1897 |
0.631 |
|
| 2011 |
Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5530-7. PMID 21775534 DOI: 10.1158/1078-0432.Ccr-10-2571 |
0.616 |
|
| 2011 |
Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, Socci ND, Viale A, de Stanchina E, Ginsberg MS, Thomas RK, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science Translational Medicine. 3: 90ra59. PMID 21734175 DOI: 10.1126/Scitranslmed.3002356 |
0.617 |
|
| 2011 |
Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W, Ladanyi M, Miller VA. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1616-22. PMID 21135146 DOI: 10.1158/1078-0432.Ccr-10-2692 |
0.617 |
|
| 2011 |
Chmielecki J, Peifer M, Viale A, Socci N, Jia P, Zhao Z, Thomas R, Pao W. Abstract LB-236: Identifying novel kinase fusions via targeted DNA capture and next-generation sequencing Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-236 |
0.638 |
|
| 2011 |
Chmielecki J, Peifer M, Viale A, Hutchinson K, Giltnane J, Socci ND, Yenamandra A, Jagasia M, Kim AS, Dave U, Thomas RK, Pao W. Abstract 4977: Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables discovery of a novel C6orf204-PDGFRβ fusion in a patient with T-ALL and eosinophilia Cancer Research. 71: 4977-4977. DOI: 10.1158/1538-7445.Am2011-4977 |
0.583 |
|
| 2011 |
Gao SP, Mao N, Schori E, Liu S, Daly L, Barlas A, Gueorguiev VD, Zhao H, Qiu J, Hefter B, Regales L, Chmielecki J, Pao W, Bromberg JF. Abstract 4689: Inhibition of IL-6/Jak/Stat3 signaling: a novel and potent targeting therapy for lung cancer Cancer Research. 71: 4689-4689. DOI: 10.1158/1538-7445.Am2011-4689 |
0.607 |
|
| 2010 |
Chmielecki J, Pao W. Highly active antitumor therapy (HAATT) for epidermal growth factor receptor-mutant lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5371-3. PMID 21062927 DOI: 10.1158/1078-0432.Ccr-10-2405 |
0.615 |
|
| 2010 |
Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews. Cancer. 10: 760-74. PMID 20966921 DOI: 10.1038/Nrc2947 |
0.62 |
|
| 2010 |
Chmielecki J, Peifer M, Jia P, Socci ND, Hutchinson K, Viale A, Zhao Z, Thomas RK, Pao W. Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Research. 38: 6985-96. PMID 20587502 DOI: 10.1093/Nar/Gkq579 |
0.589 |
|
| 2010 |
Chmielecki J, Pietanza MC, Kris M, Miller V, Stout T, Pao W. Abstract 1774: Selection for the EGFR T790M gatekeeper resistance mutation may vary among different small molecule EGFR TKIs Cancer Research. 70: 1774-1774. DOI: 10.1158/1538-7445.Am10-1774 |
0.562 |
|
| 2010 |
Chmielecki J, Peifer M, Jia P, Socci ND, Hutchinson K, Viale A, Zhao Z, Thomas RK, Pao W. Abstract A18: A novel targeted capture and massively parallel sequencing platform for systematic discovery of tyrosine kinase fusions in cancer Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcme10-A18 |
0.595 |
|
| 2009 |
Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America. 106: 9435-40. PMID 19478061 DOI: 10.1073/Pnas.0900571106 |
0.621 |
|
| 2007 |
Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X, Pao W. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. Plos Medicine. 4: e294. PMID 17927446 DOI: 10.1371/Journal.Pmed.0040294 |
0.608 |
|
| Show low-probability matches. |